published meta-analysis   sensitivity analysis   studies

sabizabulin in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsVERU-111, 2022 0.30 [0.14; 0.64] 0.30[0.14; 0.64]VERU-111, 202210%150NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-20 00:52 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 1348 - roots T: 290